Sign in

Private company

AVEO PHARMACEUTICALS, INC.

Pharmaceutical preparations company1

In its 2022 annual report the company says: “We are a commercial stage, oncology-focused biopharmaceutical company committed to delivering medicines that provide a better life for patients with cancer. We continue to develop tivozanib in immuno-oncology combinations in RCC and other indications, and we have other investigational programs in clinical development.”62 It is headquartered in Boston, Massachusetts.1

Last updated Oct 21, 2026.

Overview

  • IndustryPharmaceutical Preparations1
  • HeadquartersBoston, Massachusetts1
  • Business address30 Winter Street, Boston, Ma 021082
  • Filer categoryNon-accelerated filer, Smaller reporting company2

See how the biggest companies compare on our leaderboards

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2021

-117.2%Operating margin3
-126.1%Net margin3
602.7%Revenue growth, 20213
-116.3%Return on equity3
-$57.3MFree cash flow3

Where the money goes

Where each dollar of revenue went, fiscal 2021

  • Cost of revenue5¢$4.7M
  • Research and development29¢$26.3M
  • Selling, general and admin66¢$60.8M

Out of $42.3M in revenue.3 The company lost money this year.

Financial statements

Revenue45673$42.3M in 2021+122% since 2015
0$20.0M$40.0M$60.0M2015: $19.0M$19.0M20152016: $2.5M$2.5M2016−87%2017: $7.6M$7.6M2017+201%2018: $5.4M$5.4M2018−29%2019: $28.8M$28.8M2019+432%2020: $6.0M$6.0M2020−79%2021: $42.3M$42.3M2021+603%
Operating income45673-$49.6M in 2021+299% since 2015
-$60.0M-$40.0M-$20.0M02015: -$12.4M-$12.4M20152016: -$29.4M-$29.4M2016+137%2017: -$28.8M-$28.8M2017−2%2018: -$25.4M-$25.4M2018−12%2019: -$374.0K-$374.0K2019−99%2020: -$38.9M-$38.9M2020+10295%2021: -$49.6M-$49.6M2021+27%
Net income45673-$53.3M in 2021+256% since 2015
-$80.0M-$60.0M-$40.0M-$20.0M0$20.0M2015: -$15.0M-$15.0M20152016: -$26.9M-$26.9M2016+79%2017: -$65.0M-$65.0M2017+142%2018: -$5.3M-$5.3M2018−92%2019: $9.4M$9.4M20192020: -$35.6M-$35.6M20202021: -$53.3M-$53.3M2021+50%
Fiscal year2015201620172018201920202021
Revenue$19.0M4$2.5M5$7.6M6$5.4M7$28.8M3$6.0M3$42.3M3
Cost of revenue$03$03$4.7M3
Research and development$12.9M4$23.7M5$25.2M6$20.7M7$18.0M3$22.7M3$26.3M3
Selling, general and admin$10.8M7$11.2M3$22.2M3$60.8M3
Operating expenses$91.8M3
Operating income-$12.4M4-$29.4M5-$28.8M6-$25.4M7-$374.0K3-$38.9M3-$49.6M3
Interest$2.3M4$1.9M5$2.4M6$2.2M7$1.8M7$1.6M7
Income tax$101.0K5$101.0K6$06$07$03$03
Net income-$15.0M4-$26.9M5-$65.0M6-$5.3M7$9.4M3-$35.6M3-$53.3M3
Earnings per share-$0.395-$6.146-$0.447$0.613-$1.663-$1.633
Earnings per share (diluted)-$0.395-$6.146-$1.937$0.613-$1.663-$1.633
Shares (weighted, basic)32.7M shares3
Shares (weighted, diluted)32.7M shares3

Compare AVEO PHARMACEUTICALS, INC. with another company

Corporate structure

AVEO PHARMACEUTICALS, INC. sits at the top of its group. 1 entity on record. Switch between the flow chart and the network, and select any entity to see its details.

Major holders of AVEO PHARMACEUTICALS, INC.

  • AVEO PHARMACEUTICALS, INC. Boston, Massachusetts

Built from major holders from Schedules 13D and 13G. Each entity in the chart links to its source.

What it owns

What AVEO PHARMACEUTICALS, INC. reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Property and equipment

ItemLatestA year beforeChange
Property and equipment, net$276.0K3 Dec 31, 2021$343.0K3 Dec 31, 2020−19.5%
Operating-lease assets (leased space)$178.0K3 Dec 31, 2021$903.0K3 Dec 31, 2020−80.3%

Investments

ItemLatestA year beforeChange
Cash and cash equivalents$70.5M3 Dec 31, 2021$61.8M3 Dec 31, 2020+14.2%
Marketable securities, current$16.8M3 Dec 31, 2021$03 Dec 31, 2020

Inventory

ItemLatestA year beforeChange
Inventory, total$1.7M3 Dec 31, 2021$03 Dec 31, 2020

Leadership

Who has led AVEO PHARMACEUTICALS, INC., and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. Ngoc Tuan Ha2010–2014
  2. Michael P. Bailey2015–2023

President

  1. Ngoc Tuan Ha2011–2012
  2. Michael P. Bailey2015–2023

Chief financial officer

  1. Keith S. Ehrlich2015–2017
  2. Matthew D. Dallas2017–2019
  3. Erick Lucera2020–2023

Chief operating officer

  1. Elan Ezickson2013
  2. Jebediah Ledell2021–2023
201520202025
Board members and other officers (26)

Former names

  • AVEO PHARMACEUTICALS INCApr 27, 2005 to Apr 23, 20202

Timeline

  1. Jan 19, 20238-K Ended a material agreement; Completed an acquisition or sale; Listing notice or transfer44
  2. Jan 18, 20238-K Other events45
  3. Jan 5, 20238-K Shareholder vote46
  4. Dec 2, 20228-K Other events47
  5. Nov 7, 20228-K Results of operations48
  6. Oct 18, 20228-K Entered a material agreement; Bylaws or fiscal year changed; Other events49
  7. Aug 9, 20228-K Regulation FD disclosure50
  8. Aug 4, 20228-K Results of operations51
  9. Jun 8, 20228-K Change to shareholders' rights; Executive or director change; Bylaws or fiscal year changed52
  10. May 6, 20228-K Regulation FD disclosure53
  11. May 5, 20228-K Results of operations54
  12. Apr 8, 20228-K Entered a material agreement55
  13. Jan 8, 2015New chief executive Michael P. Bailey becomes CEO12
  14. Mar 11, 2010New chief executive Ngoc Tuan Ha becomes CEO13

Calendar

When it reported results

  1. Nov 7, 2022Reported quarterly or annual results48
  2. Aug 4, 2022Reported quarterly or annual results51
  3. May 5, 2022Reported quarterly or annual results54
  4. Mar 14, 2022Reported quarterly or annual results56
  5. Nov 8, 2021Reported quarterly or annual results57

Drug trials and FDA: coming up

  1. Aug 2027Phase 3 trial readout expected Phase 3 trial of Ficlatuzumab and Cetuximab in Metastatic Head-and-neck Squamous-cell Carcinoma: primary completion expected Aug 2027 (ClinicalTrials.gov NCT06064877).58

Drug trials and FDA: recently

  1. Jan 20, 2026Phase 3 trial completed Phase 3 trial of Tivozanib and Nivolumab in Renal Cell Carcinoma: primary completion Jan 20, 2026, no results posted yet (ClinicalTrials.gov NCT04987203).59

Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). Trials from ClinicalTrials.gov, as the sponsor registered them (expected dates are the sponsor's own and often move); approvals and advisory committee meetings from the FDA. The FDA does not publish its decision (PDUFA) dates. The full markets calendar

Filings

83 filings to the SEC since October 2021: 1 annual reports, 4 quarterly reports, 16 major events, 32 insider forms, 3 large holders, 27 other. The latest 20:

  1. Jan 30, 202315-12G EDGAR
  2. Jan 23, 2023EFFECT EDGAR
  3. Jan 23, 2023EFFECT EDGAR
  4. Jan 23, 2023EFFECT EDGAR
  5. Jan 19, 202325-NSE EDGAR
  6. Jan 19, 2023POS AM EDGAR
  7. Jan 19, 2023POS AM EDGAR
  8. Jan 19, 2023POS AM EDGAR
  9. Jan 19, 2023S-8 POS EDGAR
  10. Jan 19, 2023S-8 POS EDGAR
  11. Jan 19, 2023S-8 POS EDGAR
  12. Jan 19, 2023S-8 POS EDGAR
  13. Jan 19, 2023S-8 POS EDGAR
  14. Jan 19, 2023S-8 POS EDGAR
  15. Jan 19, 2023S-8 POS EDGAR
  16. Jan 19, 20238-K EDGAR
  17. Jan 19, 20234 FORM 4 SUBMISSION EDGAR
  18. Jan 19, 20234 FORM 4 SUBMISSION EDGAR
  19. Jan 19, 20234 FORM 4 SUBMISSION EDGAR
  20. Jan 19, 20234 FORM 4 SUBMISSION EDGAR

The 83 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

SEC filer profile

How AVEO PHARMACEUTICALS, INC. is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

  • Name on EDGARAVEO PHARMACEUTICALS, INC.1
  • CIK0001325879
  • Employer ID (EIN)04-35816501
  • Filer statusNon-accelerated filer<br>smaller reporting company1
  • Fiscal year endsDecember 311
  • Industry code (SIC)2834 Pharmaceutical Preparations1
  • Business address30 Winter Street, Boston, MA 021081
  • Phone857-400-01011
  • Shares outstanding34,763,127 as of Nov 3, 20229
  • Public float$199.9M as of Jun 30, 20213
  • On EDGAR sinceApr 27, 20051
  • Filings1,019 in all: 4 (472), 8-K (192), 3 (49), 10-Q (39), SC 13G/A (30), CT ORDER (28), DEFA14A (20), SC 13G (17)1
    All 45 form types

    424B5 (16), DEF 14A (13), EFFECT (13), 10-K (12), CORRESP (12), 4/A (10), UPLOAD (10), S-3 (7), S-8 (7), S-8 POS (7), 424B3 (6), PRE 14A (6), SC 13D/A (6), POS AM (5), S-1/A (5), 8-K/A (4), ARS (4), 10-K/A (3), D (3), 3/A (2), FWP (2), NT 10-K (2), REGDEX (2), S-1 (2), 10-Q/A (1), 15-12G (1), 25-NSE (1), 424B4 (1), 5 (1), 8-A12B (1), AW (1), CERTNAS (1), DEFM14A (1), PREM14A (1), REGDEX/A (1), S-1MEF (1), SC 13D (1)

  • Latest filingsAnnual report (10-K) Mar 14, 2022
    Quarterly report (10-Q) Nov 7, 2022
    Proxy statement (DEF 14A) Apr 26, 2022
    Latest 8-K (8-K) Jan 19, 2023

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28
  29. 29
  30. 30
  31. 31
  32. 32
  33. 33
  34. 34
  35. 35
  36. 36
  37. 37
  38. 38
  39. 39
  40. 40
  41. 41
  42. 42
  43. 43
  44. 44
  45. 45
    SEC EDGAROther events
  46. 46
  47. 47
    SEC EDGAROther events
  48. 48
  49. 49
  50. 50
  51. 51
  52. 52
  53. 53
  54. 54
  55. 55
  56. 56
  57. 57
  58. 58
  59. 59
  60. 60
  61. 61
  62. 62